IHM-antiCTLA4

N/A

Report date: 2025/03/20 15:00:56

Base Information

Drug NameIHM-antiCTLA4
Drug Alias NameCTLA-4 checkpoint inhibitor (MaxiVax)
ClassificationCell and gene therapy > Cell therapyVaccines > Application > Therapeutic vaccine
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulantsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsGranulocyte-macrophage colony-stimulating factor receptorCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMaxivax Sa
China Registration ClassN/A

Develop Information

Active CompaniesMaxivax Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A